Table 3 Key clinical trials of EphA2 targeted therapy in cancer
Agent or approaches | Trial identifier | Study characteristics | Intervention | Status |
|---|---|---|---|---|
MEDI-547 | NCT00796055 | Phase 1, n = 6 EphA2-positive solid tumor | IV infusion with MEDI-547 0.08 mg/kg on day 1 of 21-day cycle Primary outcome: safety and tolerability | Terminated |
DS-8895a | NCT02252211 | Phase 1, n = 9 EphA2-positive solid tumor | Infusion with ^89Zr-Df-DS-8895a 0.2 mg/kg i.v on day 1. DS-8895a 1, 3, or 10 mg/kg on days 8 and 22, and ^89Zr-Df-DS-8895a 1, 3, or 10 mg/kg on day 36 Primary outcome: toxicity | Completed |
DS-8895a | NCT02004717 | Phase 1, n = 37 Solid tumor | Step 1: IV infusion with DS-8895a 0.1, 0.3, 1, 5, 10, or 20 mg/kg on day 1 of 14-day cycle; step 2: IV infusion with DS-8895a 20 mg/kg on day 1 of 14-day cycle Primary outcome: toxicity, serum pharmacokinetics | Completed |
CAR-T cell | NCT02575261 | Phase 1/2, n = 60 EphA2-positive glioma | Primary outcome: effectiveness | Completed |
CAR-T cell | NCT03423992 | Phase 1, n = 100 Recurrent glioma | Primary outcome: adverse events | Ongoing |
BT5528 | NCT04180371 | Phase 1/2, n = 152 Solid tumor | IV infusion of BT5528 once a week (days 1, 8, 15, and 22) on a 4-week cycle with or without 480 mg nivolumab Primary outcome: safety, MDT | Ongoing |
SiRNA-EphA2-DOPC | NCT01591356 | Phase 1, n = 40 Advanced solid tumor | IV infusion of siRNA-EphA2-DOPC on days 1 and 4 of 21-day cycle Primary outcome: safety, MDT, and ORR | Ongoing |
MM-310 | NCT03076372 | Phase 1, n = 34 Solid tumor | IV infusion of MM-310 on day 1 of 21-day cycle Primary outcome: MDT | Ongoing |
Vaccine | NCT02754362 | Phase 2, n = 30 Recurrent glioblastoma | Block 1: bevacizumab every 2 weeks for 2 doses; block 2: vaccine + poly-ICLC + bevacizumab on weeks 1, 3, 5, and 7; block 3: vaccine + poly-ICLC monthly and bevacizumab every 2 weeks for 10 months Primary outcome: immune response, tumor response | Active, not recruiting |